Literature DB >> 29859984

Patients With Cirrhosis Require More Fecal Microbiota Capsules to Cure Refractory and Recurrent Clostridium difficile Infections.

Patricia L Pringle1, Mariam Torres Soto2, Raymond T Chung3, Elizabeth Hohmann2.   

Abstract

The incidence of recurrent and refractory Clostridium difficile (rCDI) is increasing.1 Cirrhotic patients are at increased risk of CDI as a result of frequent hospitalizations, prophylactic antibiotics, proton pump inhibitor use, and comorbidities.2 In addition, cirrhotic patients with CDI have a higher mortality rate, longer length of stay, and a higher cost compared with noncirrhotic patients.3.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29859984     DOI： 10.1016/j.cgh.2018.05.038

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  10 in total

Review 1.  A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Hepatic Encephalopathy and Clostridioides difficile Infection in Patients With Cirrhosis.

Authors:  Kyaw Min Tun; Annie S Hong; Kavita Batra; Yassin Naga; Gordon Ohning
Journal:  Cureus       Date:  2022-05-31

Review 2.  Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.

Authors:  Tae-Geun Gweon; Yoo Jin Lee; Kyeong Ok Kim; Sung Kyun Yim; Jae Seung Soh; Seung Young Kim; Jae Jun Park; Seung Yong Shin; Tae Hee Lee; Chang Hwan Choi; Young-Seok Cho; Dongeun Yong; Jin-Won Chung; Kwang Jae Lee; Oh Young Lee; Myung-Gyu Choi; Miyoung Choi
Journal:  J Neurogastroenterol Motil       Date:  2022-01-30       Impact factor: 4.924

Review 3.  The microbiota in cirrhosis and its role in hepatic decompensation.

Authors:  Jonel Trebicka; Jane Macnaughtan; Bernd Schnabl; Debbie L Shawcross; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

Review 4.  Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 33.883

5.  Faecal microbiota transplantation as a home therapy to frail older people.

Authors:  Simon Mark Dahl Jørgensen; Tone Maria Mørck Rubak; Else Marie Damsgaard; Jens Frederik Dahlerup; Christian Lodberg Hvas
Journal:  Age Ageing       Date:  2020-10-23       Impact factor: 10.668

6.  Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials.

Authors:  Jasmohan S Bajaj; Amirhossein Shamsaddini; Andrew Fagan; Richard K Sterling; Edith Gavis; Alexander Khoruts; Michael Fuchs; Hannah Lee; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Hepatol Commun       Date:  2020-11-21

7.  Systematic review with meta-analysis: encapsulated faecal microbiota transplantation - evidence for clinical efficacy.

Authors:  Frederik Cold; Simon Mark Dahl Baunwall; Jens Frederik Dahlerup; Andreas Munk Petersen; Christian Lodberg Hvas; Lars Hestbjerg Hansen
Journal:  Therap Adv Gastroenterol       Date:  2021-08-31       Impact factor: 4.409

8.  Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient.

Authors:  Patricia P Bloom; John Donlan; Mariam Torres Soto; Michael Daidone; Elizabeth Hohmann; Raymond T Chung
Journal:  Hepatol Commun       Date:  2022-04-05

9.  Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis.

Authors:  Yao-Wen Cheng; Dana Alhaffar; Srishti Saha; Sahil Khanna; Matthew Bohm; Emmalee Phelps; Marwan Ghabril; Eric Orman; Sagi Sashidhar; Nicholas Rogers; Huiping Xu; Alexander Khoruts; Byron Vaughn; Dina Kao; Karen Wong; Giovanni Cammarota; Gianluca Ianiro; Tanvi Dhere; Colleen S Kraft; Nirja Mehta; Michael H Woodworth; Jessica R Allegretti; Lotem Nativ; Jenna Marcus; Najwa El-Nachef; Monika Fischer
Journal:  Clin Gastroenterol Hepatol       Date:  2020-07-06       Impact factor: 13.576

10.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.